Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by LithLoveron Jun 21, 2021 12:57pm
124 Views
Post# 33420798

RE:RE:RE:RE:RE:Recorded Message From CEO

RE:RE:RE:RE:RE:Recorded Message From CEOI will say that had the board asked for a vote on 5:1 or anything higher I would be thinking twice.  But a 2:1 with the recent changes to the site, Care Oncology deal, the FAQ on the deal, the recent online interviews and maybe more this week (wink wink).  I have no issue supporting the board with the 2:1.

Am I happy with how things have worked out on Aristotle so far.  Of course not.  Do I see very positive changes and the company working on execution to roll this out.  Yes I do.  

A 2:1 r/s over the next 12 months has way more reward than risk.  They don't need it for financing as they have enough free shares if they wanted a PP.  Doing it now to get a $1 share price won't change anything so I have to believe it will be used for something else when needed.

Voting against it is just bashers trying to continue the short attack or uninformed shareholders who are just upset and not seeing the future here. Shooting themselves in the foot because they allowed bashers to get in their heads.

If you don't think stage can turn this around than sell and move on.  Why would you stay?

If you think they are back on the right track than vote for the 2:1 and let them execute


Mykndrsn wrote: Another genius with more knowledge, insight and experience than the CEO and board of directors. Please share your qualifications. 


<< Previous
Bullboard Posts
Next >>